KPTI – Karyopharm Therapeutics Inc
KPTI — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
21.14
Margin Of Safety %
Put/Call OI Ratio
0.48
EPS Next Q Diff
1.13
EPS Last/This Y
12.96
EPS This/Next Y
0.55
Price
7.22
Target Price
12.86
Analyst Recom
1.38
Performance Q
-2.57
Upside
-8,168.0%
Beta
0.45
Ticker: KPTI
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | KPTI | 8.49 | 0.41 | 0.31 | 75440 |
| 2026-03-10 | KPTI | 8.25 | 0.40 | 4.37 | 77623 |
| 2026-03-11 | KPTI | 8.81 | 0.41 | 13.03 | 78040 |
| 2026-03-12 | KPTI | 7.9 | 0.48 | 0.06 | 82572 |
| 2026-03-13 | KPTI | 7.9 | 0.48 | 0.08 | 82572 |
| 2026-03-17 | KPTI | 8.47 | 0.48 | 1.19 | 91419 |
| 2026-03-18 | KPTI | 8.39 | 0.50 | 0.97 | 100696 |
| 2026-03-20 | KPTI | 7.61 | 0.53 | 0.98 | 107700 |
| 2026-03-25 | KPTI | 5.22 | 0.49 | 2.16 | 93805 |
| 2026-03-26 | KPTI | 5.58 | 0.50 | 0.45 | 93777 |
| 2026-03-27 | KPTI | 5.48 | 0.50 | 3.48 | 93754 |
| 2026-03-30 | KPTI | 5.32 | 0.50 | 14.96 | 93709 |
| 2026-03-31 | KPTI | 5.57 | 0.49 | 0.02 | 93157 |
| 2026-04-01 | KPTI | 5.82 | 0.48 | 0.14 | 93252 |
| 2026-04-06 | KPTI | 6.31 | 0.48 | 0.01 | 93500 |
| 2026-04-07 | KPTI | 7.22 | 0.48 | 2.02 | 93515 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | KPTI | 8.49 | 52.7 | - | -4.34 |
| 2026-03-10 | KPTI | 8.25 | 52.7 | - | -4.34 |
| 2026-03-11 | KPTI | 8.80 | 52.7 | - | -4.34 |
| 2026-03-12 | KPTI | 7.90 | 52.7 | - | -4.34 |
| 2026-03-13 | KPTI | 7.86 | 52.7 | - | -4.34 |
| 2026-03-17 | KPTI | 8.47 | 52.7 | - | -4.34 |
| 2026-03-18 | KPTI | 8.38 | 52.7 | - | -4.34 |
| 2026-03-19 | KPTI | 7.73 | 52.7 | - | -4.34 |
| 2026-03-20 | KPTI | 7.63 | 52.7 | - | -4.34 |
| 2026-03-23 | KPTI | 6.69 | 52.7 | - | -4.34 |
| 2026-03-24 | KPTI | 5.44 | 52.7 | - | -4.34 |
| 2026-03-25 | KPTI | 5.22 | 52.7 | - | -4.34 |
| 2026-03-26 | KPTI | 5.57 | 52.7 | - | -4.34 |
| 2026-03-27 | KPTI | 5.49 | 52.7 | - | -4.34 |
| 2026-03-30 | KPTI | 5.32 | 52.7 | - | -4.34 |
| 2026-03-31 | KPTI | 5.57 | 52.7 | - | -4.34 |
| 2026-04-01 | KPTI | 5.82 | 52.7 | - | -4.34 |
| 2026-04-02 | KPTI | 5.90 | 52.7 | - | -4.34 |
| 2026-04-06 | KPTI | 6.32 | 46.9 | - | -4.97 |
| 2026-04-07 | KPTI | 7.22 | 46.9 | - | -4.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | KPTI | -1.90 | 33.39 | 14.52 |
| 2026-03-10 | KPTI | -1.90 | 33.39 | 14.52 |
| 2026-03-11 | KPTI | -1.90 | 33.39 | 17.49 |
| 2026-03-12 | KPTI | -1.90 | 33.39 | 17.49 |
| 2026-03-13 | KPTI | -1.90 | 33.39 | 17.49 |
| 2026-03-18 | KPTI | -1.72 | 33.39 | 17.49 |
| 2026-03-19 | KPTI | -1.72 | 33.39 | 17.49 |
| 2026-03-20 | KPTI | -1.72 | 33.39 | 17.49 |
| 2026-03-23 | KPTI | -1.72 | 33.59 | 17.49 |
| 2026-03-24 | KPTI | -1.72 | 33.59 | 17.49 |
| 2026-03-25 | KPTI | -1.72 | 33.59 | 21.14 |
| 2026-03-26 | KPTI | -1.72 | 33.59 | 21.14 |
| 2026-03-27 | KPTI | -1.72 | 33.59 | 21.14 |
| 2026-03-30 | KPTI | -1.72 | 30.70 | 21.14 |
| 2026-03-31 | KPTI | -1.72 | 30.70 | 21.14 |
| 2026-04-01 | KPTI | -1.72 | 30.70 | 21.14 |
| 2026-04-02 | KPTI | -1.72 | 30.70 | 21.14 |
| 2026-04-06 | KPTI | -1.69 | 41.11 | 21.14 |
| 2026-04-07 | KPTI | -1.69 | 41.11 | 21.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-2.23
Avg. EPS Est. Current Quarter
-1.31
Avg. EPS Est. Next Quarter
-1.1
Insider Transactions
-1.69
Institutional Transactions
41.11
Beta
0.45
Average Sales Estimate Current Quarter
31
Average Sales Estimate Next Quarter
34
Fair Value
Quality Score
73
Growth Score
38
Sentiment Score
48
Actual DrawDown %
96.7
Max Drawdown 5-Year %
-98.4
Target Price
12.86
P/E
Forward P/E
PEG
P/S
1.11
P/B
P/Free Cash Flow
EPS
-16.62
Average EPS Est. Cur. Y
-4.97
EPS Next Y. (Est.)
-4.41
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-134.21
Relative Volume
1.03
Return on Equity vs Sector %
39.5
Return on Equity vs Industry %
56
EPS 1 7Days Diff
-0.6
EPS 1 30Days Diff
-1.54
EBIT Estimation
◆
KPTI
Healthcare
$7.21
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
52.2
Range 1M
52.7%
Sup Dist
17.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
75.6%
EPS NY
27.2%
52W%
47.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+78.4% upside
Upside
+78.4%
Quality
73
Karyopharm Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 228
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI
Latest News
—
Caricamento notizie per KPTI…
stock quote shares KPTI – Karyopharm Therapeutics Inc Stock Price stock today
news today KPTI – Karyopharm Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch KPTI – Karyopharm Therapeutics Inc yahoo finance google finance
stock history KPTI – Karyopharm Therapeutics Inc invest stock market
stock prices KPTI premarket after hours
ticker KPTI fair value insiders trading